The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Infectious Disease Point of Care Diagnostics Market Research Report 2025

Global Infectious Disease Point of Care Diagnostics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1711365

No of Pages : 107

Ask Your Query
Synopsis
Point-of-care diagnosis is a test performed on the site of patient care that provides immediate results.Infectious diseases are caused by various microorganisms, such as viruses, bacteria, fungi and parasites.Instant diagnosis of infectious diseases can improve disease management and detection, reducing the time between disease testing and diagnosis of infection.It also reduces postoperative care time, improves outcomes, improves accuracy of outcomes, and provides a simple way to diagnose infectious diseases, broadly reducing the risk of HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections.
The global Infectious Disease Point of Care Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Infectious Disease Point of Care Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infectious Disease Point of Care Diagnostics.
Report Scope
The Infectious Disease Point of Care Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Infectious Disease Point of Care Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Infectious Disease Point of Care Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott
Siemens
GE Healthcare
Accriva
Terumo
BioMerieux
Diasorin
Roche
Danaher Corporation
BD
Bio-Rad Laboratories
Cavidi
Cepheid
Diaxonhit
Eiken Chemical
EMD Millipore
Epitope Diagnostic
Euroimmun
Gold Standard Diagnostics
Hologic
Immunetics
InBios International
Segment by Type
Over-the-counter (OTC) Testing Kits
Prescription-based Testing Kits
Segment by Application
Bacterial Infections
Fungal Infection
Virus Infection
Cardiovascular Infection
Gastrointestinal Infection
Sexually Transmitted Disease (STD) Infection
Central Nervous System Infection
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Infectious Disease Point of Care Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Infectious Disease Point of Care Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Over-the-counter (OTC) Testing Kits
1.2.3 Prescription-based Testing Kits
1.3 Market by Application
1.3.1 Global Infectious Disease Point of Care Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Bacterial Infections
1.3.3 Fungal Infection
1.3.4 Virus Infection
1.3.5 Cardiovascular Infection
1.3.6 Gastrointestinal Infection
1.3.7 Sexually Transmitted Disease (STD) Infection
1.3.8 Central Nervous System Infection
1.3.9 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Infectious Disease Point of Care Diagnostics Market Perspective (2019-2030)
2.2 Infectious Disease Point of Care Diagnostics Growth Trends by Region
2.2.1 Global Infectious Disease Point of Care Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Infectious Disease Point of Care Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Infectious Disease Point of Care Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Infectious Disease Point of Care Diagnostics Market Dynamics
2.3.1 Infectious Disease Point of Care Diagnostics Industry Trends
2.3.2 Infectious Disease Point of Care Diagnostics Market Drivers
2.3.3 Infectious Disease Point of Care Diagnostics Market Challenges
2.3.4 Infectious Disease Point of Care Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Infectious Disease Point of Care Diagnostics Players by Revenue
3.1.1 Global Top Infectious Disease Point of Care Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Infectious Disease Point of Care Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Infectious Disease Point of Care Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Infectious Disease Point of Care Diagnostics Revenue
3.4 Global Infectious Disease Point of Care Diagnostics Market Concentration Ratio
3.4.1 Global Infectious Disease Point of Care Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Infectious Disease Point of Care Diagnostics Revenue in 2023
3.5 Infectious Disease Point of Care Diagnostics Key Players Head office and Area Served
3.6 Key Players Infectious Disease Point of Care Diagnostics Product Solution and Service
3.7 Date of Enter into Infectious Disease Point of Care Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Infectious Disease Point of Care Diagnostics Breakdown Data by Type
4.1 Global Infectious Disease Point of Care Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Infectious Disease Point of Care Diagnostics Forecasted Market Size by Type (2025-2030)
5 Infectious Disease Point of Care Diagnostics Breakdown Data by Application
5.1 Global Infectious Disease Point of Care Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Infectious Disease Point of Care Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Infectious Disease Point of Care Diagnostics Market Size (2019-2030)
6.2 North America Infectious Disease Point of Care Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Infectious Disease Point of Care Diagnostics Market Size by Country (2019-2024)
6.4 North America Infectious Disease Point of Care Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Infectious Disease Point of Care Diagnostics Market Size (2019-2030)
7.2 Europe Infectious Disease Point of Care Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Infectious Disease Point of Care Diagnostics Market Size by Country (2019-2024)
7.4 Europe Infectious Disease Point of Care Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Infectious Disease Point of Care Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Infectious Disease Point of Care Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Infectious Disease Point of Care Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Infectious Disease Point of Care Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Infectious Disease Point of Care Diagnostics Market Size (2019-2030)
9.2 Latin America Infectious Disease Point of Care Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Infectious Disease Point of Care Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Infectious Disease Point of Care Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Infectious Disease Point of Care Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Infectious Disease Point of Care Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Infectious Disease Point of Care Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Infectious Disease Point of Care Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Infectious Disease Point of Care Diagnostics Introduction
11.1.4 Abbott Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.1.5 Abbott Recent Development
11.2 Siemens
11.2.1 Siemens Company Detail
11.2.2 Siemens Business Overview
11.2.3 Siemens Infectious Disease Point of Care Diagnostics Introduction
11.2.4 Siemens Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.2.5 Siemens Recent Development
11.3 GE Healthcare
11.3.1 GE Healthcare Company Detail
11.3.2 GE Healthcare Business Overview
11.3.3 GE Healthcare Infectious Disease Point of Care Diagnostics Introduction
11.3.4 GE Healthcare Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.3.5 GE Healthcare Recent Development
11.4 Accriva
11.4.1 Accriva Company Detail
11.4.2 Accriva Business Overview
11.4.3 Accriva Infectious Disease Point of Care Diagnostics Introduction
11.4.4 Accriva Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.4.5 Accriva Recent Development
11.5 Terumo
11.5.1 Terumo Company Detail
11.5.2 Terumo Business Overview
11.5.3 Terumo Infectious Disease Point of Care Diagnostics Introduction
11.5.4 Terumo Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.5.5 Terumo Recent Development
11.6 BioMerieux
11.6.1 BioMerieux Company Detail
11.6.2 BioMerieux Business Overview
11.6.3 BioMerieux Infectious Disease Point of Care Diagnostics Introduction
11.6.4 BioMerieux Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.6.5 BioMerieux Recent Development
11.7 Diasorin
11.7.1 Diasorin Company Detail
11.7.2 Diasorin Business Overview
11.7.3 Diasorin Infectious Disease Point of Care Diagnostics Introduction
11.7.4 Diasorin Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.7.5 Diasorin Recent Development
11.8 Roche
11.8.1 Roche Company Detail
11.8.2 Roche Business Overview
11.8.3 Roche Infectious Disease Point of Care Diagnostics Introduction
11.8.4 Roche Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.8.5 Roche Recent Development
11.9 Danaher Corporation
11.9.1 Danaher Corporation Company Detail
11.9.2 Danaher Corporation Business Overview
11.9.3 Danaher Corporation Infectious Disease Point of Care Diagnostics Introduction
11.9.4 Danaher Corporation Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.9.5 Danaher Corporation Recent Development
11.10 BD
11.10.1 BD Company Detail
11.10.2 BD Business Overview
11.10.3 BD Infectious Disease Point of Care Diagnostics Introduction
11.10.4 BD Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.10.5 BD Recent Development
11.11 Bio-Rad Laboratories
11.11.1 Bio-Rad Laboratories Company Detail
11.11.2 Bio-Rad Laboratories Business Overview
11.11.3 Bio-Rad Laboratories Infectious Disease Point of Care Diagnostics Introduction
11.11.4 Bio-Rad Laboratories Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.11.5 Bio-Rad Laboratories Recent Development
11.12 Cavidi
11.12.1 Cavidi Company Detail
11.12.2 Cavidi Business Overview
11.12.3 Cavidi Infectious Disease Point of Care Diagnostics Introduction
11.12.4 Cavidi Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.12.5 Cavidi Recent Development
11.13 Cepheid
11.13.1 Cepheid Company Detail
11.13.2 Cepheid Business Overview
11.13.3 Cepheid Infectious Disease Point of Care Diagnostics Introduction
11.13.4 Cepheid Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.13.5 Cepheid Recent Development
11.14 Diaxonhit
11.14.1 Diaxonhit Company Detail
11.14.2 Diaxonhit Business Overview
11.14.3 Diaxonhit Infectious Disease Point of Care Diagnostics Introduction
11.14.4 Diaxonhit Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.14.5 Diaxonhit Recent Development
11.15 Eiken Chemical
11.15.1 Eiken Chemical Company Detail
11.15.2 Eiken Chemical Business Overview
11.15.3 Eiken Chemical Infectious Disease Point of Care Diagnostics Introduction
11.15.4 Eiken Chemical Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.15.5 Eiken Chemical Recent Development
11.16 EMD Millipore
11.16.1 EMD Millipore Company Detail
11.16.2 EMD Millipore Business Overview
11.16.3 EMD Millipore Infectious Disease Point of Care Diagnostics Introduction
11.16.4 EMD Millipore Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.16.5 EMD Millipore Recent Development
11.17 Epitope Diagnostic
11.17.1 Epitope Diagnostic Company Detail
11.17.2 Epitope Diagnostic Business Overview
11.17.3 Epitope Diagnostic Infectious Disease Point of Care Diagnostics Introduction
11.17.4 Epitope Diagnostic Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.17.5 Epitope Diagnostic Recent Development
11.18 Euroimmun
11.18.1 Euroimmun Company Detail
11.18.2 Euroimmun Business Overview
11.18.3 Euroimmun Infectious Disease Point of Care Diagnostics Introduction
11.18.4 Euroimmun Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.18.5 Euroimmun Recent Development
11.19 Gold Standard Diagnostics
11.19.1 Gold Standard Diagnostics Company Detail
11.19.2 Gold Standard Diagnostics Business Overview
11.19.3 Gold Standard Diagnostics Infectious Disease Point of Care Diagnostics Introduction
11.19.4 Gold Standard Diagnostics Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.19.5 Gold Standard Diagnostics Recent Development
11.20 Hologic
11.20.1 Hologic Company Detail
11.20.2 Hologic Business Overview
11.20.3 Hologic Infectious Disease Point of Care Diagnostics Introduction
11.20.4 Hologic Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.20.5 Hologic Recent Development
11.21 Immunetics
11.21.1 Immunetics Company Detail
11.21.2 Immunetics Business Overview
11.21.3 Immunetics Infectious Disease Point of Care Diagnostics Introduction
11.21.4 Immunetics Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.21.5 Immunetics Recent Development
11.22 InBios International
11.22.1 InBios International Company Detail
11.22.2 InBios International Business Overview
11.22.3 InBios International Infectious Disease Point of Care Diagnostics Introduction
11.22.4 InBios International Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.22.5 InBios International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock